daclatasvir (Daklinza)
Jump to navigation
Jump to search
Indications
- treatment of refractory hepatitis C, including those with HCV genotype 1 infection[1]
- hepatitis C genotype 3
- for use in combination with sofosbuvir[2]
Contraindications
- coadministration of daclatasvir, sofosbuvir & amiodarone
Dosage
- 60 mg QD
Adverse effects
- fatigue, headache, nausea, diarrhea*
- reactivation of hepatitis B in patients with current or previous hepatitis B infection[3]
- 24% of patients with chronic hepatitis B[4]
- 1.4% with resolved hepatitis B infection[4]
* in combination with sofosbuvir
Drug interactions
- coadministration of daclatasvir, sofosbuvir & amiodarone increases risk of symptomatic bradycardia[2]
- cases requiring pacemaker intervention have been reported
Mechanism of action
- NS5A replication complex inhibitor
More general terms
References
- ↑ 1.0 1.1 Lok AS et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012 Jan 19; 366:216. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22256805
Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012 Jan 19; 366:273. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22256811 - ↑ 2.0 2.1 2.2 Brooks M FDA Clears Two New Oral Drugs for Hepatitis C. Medscape Oncology. July 24, 2015 http://www.medscape.com/viewarticle/848650
- ↑ 3.0 3.1 FDA Drug Safety Communication: Oct 4, 2016 FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
- ↑ 4.0 4.1 4.2 Mucke MM, Backus LI, Mucke VT et al Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterology & Hepatology. Jan 19, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29371017 <Internet> http://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30002-5/fulltext